Damora Therapeutics, Inc. (DMRA)
NASDAQ · Manufacturing · Pharmaceutical preparations
$20.66+$0.3900 (+1.92%) on the dayAs of the close; data may be delayed.
DMRA price, last 12 months
Key stats
- Previous close
- $20.27
- Open
- $20.80
- Day range
- $19.80 – $20.80
- 52-week range
- $16.50 – $34.89
- Volume
- 1.4M
- Avg volume (20 days)
- 800.8K
- Market cap
- $1.3B
Performance
1W−8.5%
1M−32.0%
3M−18.5%
6M−19.4%
YTD—
1Y—
Technicals and fundamentals
About Damora Therapeutics, Inc.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.3B